Group 1 - The core point of the announcement is that Jimin Health's controlling shareholder, Shuangge Group, plans to reduce its stake in the company by up to 15.75 million shares, which represents no more than 3% of the total share capital [1]

Core Viewpoint - Jimin Health (603222) announced that its shareholder, Shuangge Group, plans to reduce its holdings by up to 15.75 million shares, representing no more than 3% of the company's total share capital due to its own funding needs [1] Company Summary - Shuangge Group intends to execute the share reduction through centralized bidding and block trading methods [1] - The stock price of Jimin Health has been on an upward trend recently, closing at 11.52 yuan per share on September 4, with a maximum increase of 64.34% from August 13 to September 4 [1]

Core Viewpoint - Jimin Health (603222.SH) announced that Shuangge Group plans to reduce its stake in the company by up to 15.75 million shares, representing no more than 3% of the total share capital, due to its own funding needs [1] Summary by Relevant Sections - **Share Reduction Plan** - Shuangge Group intends to reduce its holdings through centralized bidding and block trading methods [1] - The reduction will occur within three months after the announcement, starting fifteen trading days later [1] - The maximum shares to be reduced via centralized bidding will not exceed 1% of the total share capital, while block trading will not exceed 2% [1] - **Adjustment Clause** - The number of shares to be reduced and the reduction price will be adjusted accordingly if there are any events such as dividends, stock splits, capital reserve transfers, or rights issues during the reduction period [1]

济民健康公告，持股24.37%的控股股东双鸽集团因自身资金需求，计划在2025年9月29日至2025年12月 26日，通过集中竞价及大宗交易方式合计减持不超过1575.27万股，即不超过公司总股本的3%，其中集 中竞价不超过525.09万股，大宗交易不超过1050.18万股。 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-044 济民健康管理股份有限公司 截至本减持计划公告之日，双鸽集团有限公司(以下简称"双鸽集团")持有 济民健康管理股份有限公司（以下简称"公司"）股份 127,983,520 股，占公司 总股本的 24.37%，上述股份全部来源于公司首次公开发行前已持有的股份及上 市后资本公积转增股本取得的股份。 减持计划的主要内容 双鸽集团因自身资金需求，计划以集中竞价交易方式和大宗交易方式减持公 司合计不超过 15,752,718 股股份，即不超过公司总股本的 3%（若计划减持期间 有派息、送股、资本公积金转增股本、配股等除权除息事项，拟减持股份数量和 减持价格将相应进行调整），本次减持将在本减持计划公告之日起十五个交易日 后的 3 个月内进行,其中通过集中竞价交易方式减持股份不超过公司总股本的 1%， 通过大宗交易方式减持股份不超过公司总股本的 2%。 1 股东名称 双鸽集团 股东身份 控股股东、实控人及一致行动人 √是 □否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √否 其他：不适用 一、减持主体的基本情况 本公司董事会、全 ...

人民财讯9月4日电，济民健康（603222）9月4日晚间公告，公司控股股东、实控人之一致行动人双鸽集 团有限公司计划15个交易日后的3个月内，以集中竞价和大宗交易方式，减持公司股份合计不超过 1575.27万股，即不超过公司总股本的3%。 ...

（文章来源：每日经济新闻） 每经AI快讯，9月4日，济民健康(603222.SH)公告称，公司股东双鸽集团因自身资金需求，计划以集中 竞价交易和大宗交易方式减持公司股份合计不超过1575.27万股，即不超过公司总股本的3%。减持将在 公告之日起十五个交易日后的3个月内进行，其中通过集中竞价交易方式减持不超过1%，通过大宗交易 方式减持不超过2%。减持价格将根据市场情况和公司股价进行调整。双鸽集团承诺将严格遵守相关法 律法规和监管要求，及时履行信息披露义务。 ...

济民健康（603222）(603222.SH)公告，公司股东双鸽集团计划以集中竞价交易方式和大宗交易方式减 持公司合计不超过1575.27万股股份，即不超过公司总股本的3%。 ...

智通财经APP讯，济民健康(603222.SH)公告，公司股东双鸽集团计划以集中竞价交易方式和大宗交易 方式减持公司合计不超过1575.27万股股份，即不超过公司总股本的3%。 ...

Group 1 - The medical device sector experienced a slight adjustment on September 4, outperforming the broader market, with the medical device ETF (562600) declining by 1.58% while stocks like Jimin Health and Haooubo rose by 10.03% and 6.45% respectively [1] - The medical device ETF (562600) attracted a total of 34.1 million yuan in capital over the past 10 days, indicating strong investor interest [1] - The Shaanxi Provincial Drug Administration reported achievements in high-quality drug regulation during the 14th Five-Year Plan, including 100% coverage of clinical trial supervision and inspections of 4,839 medical device production processes [1] Group 2 - Guotai Junan Securities noted that the medical device sector's revenue for Q2 2025 decreased by 4.77% year-on-year, attributed to extended revenue recognition cycles and inventory clearance needs among companies [2] - The medical device sector has seen a 23.3% increase year-to-date as of August 29, 2025, ranking 4th among sub-sectors in the pharmaceutical and biological industry, with domestic innovation support policies significantly impacting industry valuations [2] - The medical device ETF (562600) serves as a convenient tool for investors to capture growth opportunities in the medical device industry, tracking the CSI All-Share Medical Device Index, which has a high concentration of 89.34% in the medical device sector [2]